Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Non-Current Deffered Revenue: 2022-2023

Historic Non-Current Deffered Revenue for NewAmsterdam Pharma Co N.V (NAMS) over the last 2 years, with Dec 2023 value amounting to $1.0 million.

  • NewAmsterdam Pharma Co N.V's Non-Current Deffered Revenue rose 2191.02% to $222,000 in Q2 2024 from the same period last year, while for Jun 2024 it was $222,000, marking a year-over-year increase of 2191.02%. This contributed to the annual value of $1.0 million for FY2023, which is 78.74% down from last year.
  • Per NewAmsterdam Pharma Co N.V's latest filing, its Non-Current Deffered Revenue stood at $1.0 million for FY2023, which was down 78.74% from $4.8 million recorded in FY2022.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's Non-Current Deffered Revenue registered a high of $4.8 million during FY2022, and its lowest value of $1.0 million during FY2023.
  • Over the past 2 years, NewAmsterdam Pharma Co N.V's median Non-Current Deffered Revenue value was $2.9 million (recorded in 2022), while the average stood at $2.9 million.
  • Data for NewAmsterdam Pharma Co N.V's Non-Current Deffered Revenue shows a maximum YoY crashed of 78.74% (in 2023) over the last 5 years.
  • Over the past 2 years, NewAmsterdam Pharma Co N.V's Non-Current Deffered Revenue (Yearly) stood at $4.8 million in 2022, then slumped by 78.74% to $1.0 million in 2023.